7/8/05 News Brief: Product News

Share this article:

Product News
Galderma Laboratories has announced FDA approval of MetroGel (metronidazole) for the topical treatment of the inflammatory lesions of rosacea. MetroGel will be available by prescription July 29, 2005.

The FDA has accepted Santarus' new drug application for Zegerid (omeprazole) capsules 40 mg. and 20 mg. Santarus expects the FDA will complete its review or otherwise respond to the NDA by February 26, 2006. Santarus is seeking marketing approval of Zegerid Capsules for the treatment of heartburn and other symptoms associated with gastroesophageal reflux disease (GERD), erosive esophagitis, duodenal ulcers and gastric ulcers.

Par Pharmaceutical announced FDA approval of Megace ES (megestrol acetate), a concentrated oral suspension for the treatment of anorexia, cachexia, or an unexplained, significant weight loss in patients with a diagnosis of AIDS. Megace ES is the first branded pharmaceutical product developed by Par to be approved for marketing by the FDA.

Novartis and Procter & Gamble Pharmaceuticals have entered into an agreement for the co-promotion and further development of Enablex (darifenacin) extended release tablets for the treatment of overactive bladder in the U.S. Novartis will continue to record revenues for Enablex and will pay royalties to P&GP based on the product's performance.

Share this article:
You must be a registered member of MMM to post a comment.
close

Next Article in Business Briefs

Email Newsletters

MM&M EBOOK: PATIENT ACCESS

Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in Business Briefs

Monday Moves: September 15

Hires and promotions for manufacturers, regulatory and agencies

Kantar acquires Evidências, expands Brazilian presence

The company's acquisition signals the growing importance of understanding the Brazilian healthcare market and evidence-based healthcare management services.

Study says statins not enough for diabetic hearts

Researchers using an experimental test have discovered that the 50% of surveyed diabetics may also have undetected heart muscle damage.